Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

1. General considerations

Two broad classes of anti-VEGF agents have been developed for clinical application - those which directly neutralize VEGF (ligand-specific) and those which bind to and inactivate functional VEGF receptors. The first class is comprised of large molecules which tend to be administered systemically. These include bevacizumab, a humanized monoclonal antibody (mAb) which neutralizes VEGF-A, the predominantly active species of VEGF;36 and VEGF-TrapR1R2 (aflibercept, AVE 0005), a soluble decoy receptor generated by fusing the constant region of IgG1 with the ligand binding domains of two principle anti-VEGF receptors, then optimized for VEGF binding affinity and pharmacokinetics.37 The second class is comprised mostly (but not exclusively) of orally administered small molecules which tend to block tyrosine kinase activity located in the cytoplasmic domain of VEGF receptors. The exception to this is the drug ramucirumab, a monoclonal antibody which specifically recognizes the predominantly active VEGF receptor, VEGFR-2.38

It is worth discussing relative advantages and disadvantages of small molecular inhibitors (Ibs) and monoclonal antibodies (mAbs). Ibs are orally bio-available, but often require daily administration due to their relatively short half-lives. In addition, based on the route of administration, systemic levels may be more highly variable than for mAbs. While some of the Ibs (e.g. cediranib,39 pazopanib40) are almost exclusively specific for VEGFR, others target multiple signal transduction pathways in addition to that for VEGF. Examples of the latter agents include sorafenib41 and sunitinib,42 which target both VEGFR and the platelet-derived growth factor receptor (PDGFR). PDGF signal transduction appears to stimulate later phases of tumor angiogenesis involving vessel maturation (see discussion of PDGF inhibition below). MAb therapy is systemic in nature but requires less frequent administration due to longer clearance times; they are in principle more uniformly bio-distributed than Ibs. Due to affinity for single targets, they are associated with a more limited range of potential anti-tumor effects. Recent strategies have involved combinations with both mAbs and Ibs, for example the phase I/II trial of bevacizumab and sorafenib discussed later in this article.

VEGF inhibitors have demonstrated unique toxicities, some which appear to be related to interference with known physiologic effects of VEGF, and others whose mechanisms have yet to be elucidated. The largest database comes from studies of bevacizumab36, 43 in clinical trials utilizing the US National Cancer Institute (NCI) Common Toxicity Criteria (CTC),44 though the spectrum of adverse effects appears to be consistent across most VEGF inhibitors. Proteinuria is common but fortunately mild and self-limited in the vast majority of patients; nephrotic range proteinuria has been observed in only 0.5% of the treated population. Hypertension is also common, and though 8% to 18% develop grade 3 or higher blood pressure elevation, the majority of such patients can be stabilized with single agent anti-hypertensive therapy. Mucosal hemorrhage can be seen, most commonly in the form of low grade epistaxis; however, patients with central bronchogenic non-small cell lung cancers are at risk for high grade hemoptysis. Interference with wound healing has been a source of concern in the treatment of patients in the peri-operative period. Fortunately, wound dehiscense has been limited to 1% patients at potential risk. In large-scale randomized control trials of bevacizumab, the incidence of arterial thrombotic events (ATE) has been approximately 4.4% in treated subjects, compared with 1.9% in controls; risk factors include advanced age and pre-existing arterial vascular disease. Other rare but unique toxicities include reversible posterior leukoencephalopathy syndrome (RPLS), occurring in fewer than 0.1% of patients and characterized by a variety of central nervous system manifestations such as mental status changes, seizures, visual disturbance, usually with hypertension. Perhaps the most concerning adverse effect is the development of gastrointestinal perforation (GIP) or fistula. This complication has been reported in approximately 2.4% overall, and in 5% of patients with epithelial ovarian cancer. The mechanisms of GIP have not yet been elucidated; however, proposed risk factors include intestinal obstruction, ischemia, trans-mural tumor infiltration, infectious or non-infectious inflammatory bowel diseases - unlikely dose or duration of therapy.

While it is important to recognize the contribution of published historical experience, for succinctness, and in order to concentrate on the highest levels of evidence, the current article reviews only prospective clinical research. Needless to say, the integration of VEGF targeted therapeutics into clinical trials for gynecologic malignancies has been pursued enthusiastically, yet the knowledgebase generated from gynecologic cancer trials pales in comparison to that produced through research on non-gynecologic tumors. A review of the current US NCI database45 identified 51 registered trials in at least phase II development, 37 examining VEGF neutralizing agents and 15 investigating VEGFR inhibitors (one trial evaluates a combination of both drug classes). Of these 51, only 20 have been closed and published final results are available for only four studies. When one takes into account the epidemiologic aspects of gynecologic malignancies discussed earlier, it is not surprising that the 41 of these 51 clinical trials utilizing VEGF inhibitors have been focused on the treatment of EOC (including primary peritoneal and fallopian tube carcinomas).

The remainder of this article is focused on the assessment of this group of clinical trials. The information is organized first by design, then by disease site, with consideration of what has been learned, the design and rationale for investigation in progress, and future directions.

2. Single agent VEGF inhibitor trials: standard phase II studies

As demonstrated in Table 2, 17 NCI registered trials have evaluated single agent anti-VEGF activity in patients with recurrent ovarian, endometrial and cervical carcinomas. Most of these have utilized two-stage designs in patients with NCI Response Evaluation Criteria in Solid Tumor (RECIST)46 measurable disease and have evaluated primary endpoints of response rate, PFS, or the combination. Thus far, the only completed, published (or accepted for publication) trials are those involving bevacizumab; these have demonstrated single agent activity in EOC,47, 48 endometrial49 and cervical carcinoma.50

Table 2
US NCI registered single agent phase II trials of VEGF inhibitors in recurrent gynecologic cancers

• Click for larger image

For EOC, the design and results of three, phase II trials of VEGF neutralizing agent monotherapy have been reported, two examining bevacizumab47, 48 and one investigating VEGF-Trap (preliminary results published in abstract form only).51 As shown in Table 3, all three trials enrolled patients with RECIST measurable recurrent or persistent disease, yet demonstrated variable clinical activity of single agent therapy, with response rates ranging from 8% to 21% and 6-month PFS rates ranging from 4% to 40%. A recent report from the sponsor stated that the VEGF-Trap trial failed to achieve its primary endpoint of demonstrating either dose level to achieve a RECIST response rate statistically greater than 5%.52 Although it is unscientific to draw conclusions upon comparisons among separate phase II trials (and only preliminary data are available for the VEGF-Trap trial), one may hypothesize that clinical activity may be more favorable for patients with a longer interval from the completion of last platinum-containing chemotherapy, fewer prior cytotoxic regimens, and better performance status. In contradistinction, in the Gynecologic Oncology Group (GOG) trial47 an internal exploratory regression analysis failed to demonstrate any relationship of these known prognostic factors (or age) with PFS. To date there are no published pre-clinical or clinical studies prospectively comparing the anti-tumor activities of bevacizumab and VEGF-Trap.

Table 3
Phase II trials of VEGF neutralizing single agent therapy in patients with epithelial ovarian and primary peritoneal cancer

• Click for larger image

With regard to adverse effects, when taken together, these trials demonstrated that single agent anti-VEGF therapy was tolerable in general, with the expected frequency of events. The exception to this was higher than expected rate of GIP in the third line Genentech AVF 2,949 trial of bevacizumab in platinum-resistant patients.48 This trial was terminated prematurely because of 5 GIPs reported out of the first 44 patients enrolled. In October 2005, the US FDA released an Action Letter53 alerting investigators and patients to this risk, even though a black box warning was already present on the package insert. At that time, the rates of GIP were highly variable among trials, (as a distinct example, there were no events in 62 patients treated on the GOG phase II bevacizumab trial). As mentioned previously, a 2007 review of GIP by Han et al.54 the aggregate number of events reported in published bevacizumab clinical trials and institutional off-label case series of EOC was 16 (5.2%) events in 308 patients. Based on this and other historical analyses, the risk factors for GIP remain unclear; clearly large scale prospective investigation would more reliably answer this question.

3. Consolidation therapy trials

Despite the fairly obvious rationale for such an approach, the investigation of VEGF inhibitors for their potential to extend PFS or OS in high risk patients considered to be in complete remission following standard therapies has been quite limited. To date there are only two registered trials of this nature. These are active phase II randomized trials in patients with EOC. One is a placebo controlled trial of single agent sorafenib; the other is a trial of bevacizumab +/- erlotinib (an epidermal growth factor receptor 1 Ib).

4. Combinations with cytotoxic regimens

The rationale for combining cytotoxic drugs with anti-VEGF therapy stemmed initially from additive and in some cases synergistic interaction in pre-clinical models. While an additive effect might be explained by complementary, independent anti-tumor activity, multiple purported mechanisms exist to promote synergistic interaction, including sensitization to apoptosis, reversal of cytotoxic drug resistance, and increased tumor access to chemotherapeutics secondary to vascular normalization (see above).30 It has also been hypothesized that combining VEGF targeted agents with frequently administered low dose, so called metronomic chemotherapy may have additive or synergistic anti-angiogenic or anti-tumor effects.

Given the results of pre-clinical studies referenced above and multiple positive phase III trials (all with bevacizumab) in non-gynecologic cancers,55-58 it is not surprising that trials investigating anti-VEGF and cytotoxic therapy combinations in patients with gynecologic tumors have been pursued with vigor. These are listed in Table 4 and Table 5.

Table 4
National Cancer Institute registered trials of VEGF inhibitors in combination with cytotoxic agents for recurrent gynecologic cancers

• Click for larger image

Table 5
US National Cancer Institute registered front-line trials of VEGF inhibitors in combination with cytotoxic agents for gynecologic cancers

• Click for larger image

While it would appear reasonable for cytotoxic agents considered active in gynecologic cancers to be combined with anti-VEGF agents in phase II trials, many such trials have perhaps been initiated without evidence of safety or preclinical evidence of benefit, in a "cart before horse" fashion. This enthusiasm has also been reflected in multiple published multi-institutional historic cohort studies of VEGF inhibitors in recurrent EOC, endometrial and cervical cancer reflecting the utilization of VEGF inhibitors in combination with cytotoxic agents in routine clinical practice.59-66 It is unclear whether combination therapy is a better choice than single agent therapy in this setting without controlled clinical trials data.

Perhaps the first phase II trial of combined cytotoxic and anti-VEGF bevacizumab and low dose oral cyclophosphamide in 70 patients with recurrent or persistent EOC.67 Patients were treated with bevacizumab at 10 mg/kg every 14 days with 50 mg of daily oral cyclophosphamide. Based on similar eligibility criteria, patient and disease characteristics were similar to that of the GOG 170-D population. This regimen was associated with a toxicity profile similar to the single agent bevacizumab trial with the exception of 2 cases of G4 cerebral ischemia, 2 cases of pulmonary hypertension, 4 GI perforation events and 3 treatment related deaths. With regard to efficacy, 56% of patients were progression-free as of 6 months and 24% had partial clinical responses. These findings provide rationale for a phase II randomized trial of combination versus single agent therapy, but early stopping rules for excessive toxicity in such trials would be important.

Additional reports of outcomes for patients with epithelial ovarian and primary peritoneal cancers treated with bevacizumab include at least three historical case series of patients treated outside clinical trials with single agent therapy or in combination with cytotoxic drugs, suggesting activity in more heavily pre-treated patients with recurrent disease61, 63, 66 and two single arm phase II studies demonstrating the feasibility of the combination of traditional carboplatin-paclitaxel chemotherapy combined with bevacizumab in front line therapy.68, 69

Taken together, these results support the need for randomized trials to determine relative efficacy and toxicity. As shown in Table 4, four such studies are in progress for recurrent EOC. One example is GOG 213, a phase III trial of second line therapy with carboplatin and paclitaxel, with or without bevacizumab, in patients with initial platinum-free intervals of at least 6 months, with a primary endpoint of overall survival. To address the potential added benefit of secondary cytoreductive surgery, in this study, patients who are deemed to be "surgical candidates" undergo secondary randomization to surgery versus no surgery. Another is a placebo controlled trial of carboplatin and gemcitabine with or without bevacizumab in a similar population, with primary endpoint of PFS.

As demonstrated in Table 5, currently, two phase III trials of bevacizumab in front-line therapy are in progress - GOG 0218, activated September 2005 and ICON7, activated October 2006. Both trials include six cycles of standard platinum-taxane chemotherapy, but there are important differences between the two trials which should be noted. GOG 218 is a three-arm, placebo-controlled trial, whose primary objective is to determine whether the addition of bevacizumab (15 mg/kg every 21 days) to standard cytotoxic therapy, when administered concurrently, or concurrently plus extended for an additional 16 cycles, will produce an improvement in PFS. It is limited to patients with stage III or IV disease. In contrast, ICON-7 is a two-arm trial without a placebo, with the experimental arm containing bevacizumab (7.5 mg/kg every 21 days) concomitantly with cytotoxic therapy, then extended for 12 cycles, also with the primary endpoint of PFS. The patient population for the ICON trial includes all patients with at least high risk early stage disease. As far as secondary endpoints are concerned, both trials will systematically examine quality of life, and while translational research will be performed in the context of GOG 218 and a pharmaco-economic analysis is planned for ICON-7.

Clinical trials combining anti-VEGF agents with cytotoxic drugs in the treatment of endometrial and cervical cancers are relatively scarce when compared with those for EOC. Only one trial is currently active in the NCI Database, a GOG phase III randomized trial of cisplatin plus paclitaxel with or without bevacizumab vs. the non-platinum doublet, topotecan plus paclitaxel, with or without bevacizumab.

With respect to endometrial cancer, the reason for the paucity of phase III trials has mostly to do with impact on public health in industrialized nations, but there may be other explanations - relatively few indications for systemic therapy, and the observation that epithelial ovarian cancers and advanced endometrial cancers appear to be similar with respect to histologic cell types (endometrioid, serous, clear cell) and biologic behavior. Hence, the development of systemic therapy for patients with advanced endometrial cancers has tended to shadow the development of systemic therapy for patients with epithelial ovarian cancers.

The situation for carcinomas of the cervix is even more pronounced, with only 4,070 cancer deaths estimated for 2009.1 Again, in 2006, of the 9,710 annual cases of cervical cancer in the U.S., over half were classified as localized, with over 90% of patients cured using standard modalities.2 However, given that this disease is a major cause of morbidity and mortality in less industrialized regions, novel approaches to systemic therapy are still needed. Given the potential for anti-VEFG inhibitors to restore microcirculation, phase I and II trials are in progress to explore the interaction between such agents and standard chemo-radiation in the management of patients with advanced disease.

5. Combinations with other biologic targeted agents

Although conceptually attractive, the evaluation of rational combinations of anti-VEGF and other biologic agents is in its infancy. One avenue of pursuit has been cross-talk between the VEGF and EGFR-1 pathway. However, thus far preliminary data suggest lack of additional benefit for anti-EGFR-1 drugs.70 Another trial is evaluating the combination of bevacizumab with Sorafenib, attempting to exploit simultaneous blockade of VEGF and its receptors, as well as other pathways potentially involved in ovarian cancer progression.